Cargando…

The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension

This study aimed to investigate the impact of angiotensin-converting-enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) on 3-year clinical outcomes in acute myocardial infarction (AMI) patients without a history of hypertension who underwent successful percutaneous coronary i...

Descripción completa

Detalles Bibliográficos
Autores principales: Her, Ae-Young, Choi, Byoung Geol, Rha, Seung-Woon, Kim, Yong Hoon, Choi, Cheol Ung, Jeong, Myung Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703906/
https://www.ncbi.nlm.nih.gov/pubmed/33253206
http://dx.doi.org/10.1371/journal.pone.0242314
_version_ 1783616714760519680
author Her, Ae-Young
Choi, Byoung Geol
Rha, Seung-Woon
Kim, Yong Hoon
Choi, Cheol Ung
Jeong, Myung Ho
author_facet Her, Ae-Young
Choi, Byoung Geol
Rha, Seung-Woon
Kim, Yong Hoon
Choi, Cheol Ung
Jeong, Myung Ho
author_sort Her, Ae-Young
collection PubMed
description This study aimed to investigate the impact of angiotensin-converting-enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) on 3-year clinical outcomes in acute myocardial infarction (AMI) patients without a history of hypertension who underwent successful percutaneous coronary intervention (PCI) with drug-eluting stents (DES). A total of 13,104 AMI patients who were registered in the Korea AMI registry (KAMIR)-National Institutes of Health (NIH) were included in the study. The primary endpoint was 3-year major adverse cardiac events (MACE), which was defined as the composite of all-cause death, recurrent myocardial infarction (MI), and any repeat revascularization. To adjust baseline potential confounders, an inverse probability weighting (IPTW) analysis was performed. The patients were divided into two groups: the ACEI group, n = 4,053 patients and the ARB group, n = 4,107 patients. During the 3-year clinical follow-up, the cumulative incidences of MACE (hazard ratio [HR], 0.843; 95% confidence interval [CI], 0.740–0.960; p = 0.010), any repeat revascularization (HR, 0.856; 95% CI, 0.736–0.995; p = 0.044), stroke (HR, 0.613; 95% CI, 0.417–0.901; p = 0.013), and re-hospitalization due to heart failure (HF) (HR, 0.399; 95% CI, 0.294–0.541; p <0.001) in the ACEI group were significantly lower than in the ARB group. In Korean patients with AMI without a history of hypertension, the use of ACEI was significantly associated with reduced incidences of MACE, any repeat revascularization, stroke, and re-hospitalization due to HF than those with the use of ARB.
format Online
Article
Text
id pubmed-7703906
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-77039062020-12-03 The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension Her, Ae-Young Choi, Byoung Geol Rha, Seung-Woon Kim, Yong Hoon Choi, Cheol Ung Jeong, Myung Ho PLoS One Research Article This study aimed to investigate the impact of angiotensin-converting-enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) on 3-year clinical outcomes in acute myocardial infarction (AMI) patients without a history of hypertension who underwent successful percutaneous coronary intervention (PCI) with drug-eluting stents (DES). A total of 13,104 AMI patients who were registered in the Korea AMI registry (KAMIR)-National Institutes of Health (NIH) were included in the study. The primary endpoint was 3-year major adverse cardiac events (MACE), which was defined as the composite of all-cause death, recurrent myocardial infarction (MI), and any repeat revascularization. To adjust baseline potential confounders, an inverse probability weighting (IPTW) analysis was performed. The patients were divided into two groups: the ACEI group, n = 4,053 patients and the ARB group, n = 4,107 patients. During the 3-year clinical follow-up, the cumulative incidences of MACE (hazard ratio [HR], 0.843; 95% confidence interval [CI], 0.740–0.960; p = 0.010), any repeat revascularization (HR, 0.856; 95% CI, 0.736–0.995; p = 0.044), stroke (HR, 0.613; 95% CI, 0.417–0.901; p = 0.013), and re-hospitalization due to heart failure (HF) (HR, 0.399; 95% CI, 0.294–0.541; p <0.001) in the ACEI group were significantly lower than in the ARB group. In Korean patients with AMI without a history of hypertension, the use of ACEI was significantly associated with reduced incidences of MACE, any repeat revascularization, stroke, and re-hospitalization due to HF than those with the use of ARB. Public Library of Science 2020-11-30 /pmc/articles/PMC7703906/ /pubmed/33253206 http://dx.doi.org/10.1371/journal.pone.0242314 Text en © 2020 Her et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Her, Ae-Young
Choi, Byoung Geol
Rha, Seung-Woon
Kim, Yong Hoon
Choi, Cheol Ung
Jeong, Myung Ho
The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension
title The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension
title_full The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension
title_fullStr The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension
title_full_unstemmed The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension
title_short The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension
title_sort impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703906/
https://www.ncbi.nlm.nih.gov/pubmed/33253206
http://dx.doi.org/10.1371/journal.pone.0242314
work_keys_str_mv AT heraeyoung theimpactofangiotensinconvertingenzymeinhibitorsversusangiotensinreceptorblockerson3yearclinicaloutcomesinpatientswithacutemyocardialinfarctionwithouthypertension
AT choibyounggeol theimpactofangiotensinconvertingenzymeinhibitorsversusangiotensinreceptorblockerson3yearclinicaloutcomesinpatientswithacutemyocardialinfarctionwithouthypertension
AT rhaseungwoon theimpactofangiotensinconvertingenzymeinhibitorsversusangiotensinreceptorblockerson3yearclinicaloutcomesinpatientswithacutemyocardialinfarctionwithouthypertension
AT kimyonghoon theimpactofangiotensinconvertingenzymeinhibitorsversusangiotensinreceptorblockerson3yearclinicaloutcomesinpatientswithacutemyocardialinfarctionwithouthypertension
AT choicheolung theimpactofangiotensinconvertingenzymeinhibitorsversusangiotensinreceptorblockerson3yearclinicaloutcomesinpatientswithacutemyocardialinfarctionwithouthypertension
AT jeongmyungho theimpactofangiotensinconvertingenzymeinhibitorsversusangiotensinreceptorblockerson3yearclinicaloutcomesinpatientswithacutemyocardialinfarctionwithouthypertension
AT heraeyoung impactofangiotensinconvertingenzymeinhibitorsversusangiotensinreceptorblockerson3yearclinicaloutcomesinpatientswithacutemyocardialinfarctionwithouthypertension
AT choibyounggeol impactofangiotensinconvertingenzymeinhibitorsversusangiotensinreceptorblockerson3yearclinicaloutcomesinpatientswithacutemyocardialinfarctionwithouthypertension
AT rhaseungwoon impactofangiotensinconvertingenzymeinhibitorsversusangiotensinreceptorblockerson3yearclinicaloutcomesinpatientswithacutemyocardialinfarctionwithouthypertension
AT kimyonghoon impactofangiotensinconvertingenzymeinhibitorsversusangiotensinreceptorblockerson3yearclinicaloutcomesinpatientswithacutemyocardialinfarctionwithouthypertension
AT choicheolung impactofangiotensinconvertingenzymeinhibitorsversusangiotensinreceptorblockerson3yearclinicaloutcomesinpatientswithacutemyocardialinfarctionwithouthypertension
AT jeongmyungho impactofangiotensinconvertingenzymeinhibitorsversusangiotensinreceptorblockerson3yearclinicaloutcomesinpatientswithacutemyocardialinfarctionwithouthypertension